Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 1,022.8	$ 1,233.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	457.4	307.1
Share-based compensation	70.8	78.3
Change in fair value of contingent consideration	(196.5)	26.3
Impairment of intangible assets	523.3	188.0
Write down of assets	0.0	14.0
Gain on sale of product rights	(13.0)	(86.2)
Unwind of inventory fair value step-ups	23.0	90.6
Other, net	(3.8)	16.5
Movement in deferred taxes	(178.3)	63.1
Equity in losses/(earnings) of equity method investees	1.6	(3.8)
Changes in operating assets and liabilities:
Increase in accounts receivable	(288.1)	(92.1)
Iincrease in sales deduction accruals	100.0	28.2
Increase in inventory	(21.7)	(15.8)
Decrease/(increase) in prepayments and other assets	21.2	(114.7)
Increase/(decrease) in accounts and notes payable and other liabilities	56.5	(92.8)
Net cash provided by operating activities	1,575.2	1,673.5
CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash	(48.0)	(32.3)
Purchases of subsidiary undertakings and businesses, net of cash acquired	(5,553.4)	(4,104.4)
Purchases of non-current investments	(5.2)	(22.8)
Purchases of PP&E	(62.1)	(49.8)
Proceeds from short-term investments	67.0	57.8
Proceeds received on sale of product rights	14.5	122.7
Proceeds from disposal of non-current investments	18.5	21.3
Other, net	2.7	1.3
Net cash used in investing activities	(5,566.0)	(4,006.2)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long-term and short-term borrowings	3,650.8	2,310.8
Repayment of revolving line of credit and short term borrowings	(2,486.1)	(1,461.8)
Repayment of debt acquired through business combinations	0.0	(551.5)
Proceeds from ViroPharma call options	0.0	346.7
Payment of dividend	(110.2)	(99.6)
Excess tax benefit associated with exercise of stock options	30.5	37.4
Contingent consideration payments	(8.8)	(12.8)
Other, net	(21.3)	(2.0)
Net cash provided by financing activities	1,054.9	567.2
Effect of foreign exchange rate changes on cash and cash equivalents	(1.6)	(6.2)
Net decrease in cash and cash equivalents	(2,937.5)	(1,771.7)
Cash and cash equivalents at beginning of period	2,982.4	2,239.4
Cash and cash equivalents at end of period	44.9	467.7
Supplemental information associated with continuing operations:
Interest (paid)/received	(13.1)	8.0
Income taxes paid	(97.5)	(156.3)
Income taxes repaid	$ 77.0	232.6
Continung operations
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights		(86.2)
Discontinued operations
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights		33.6
Total
Adjustments to reconcile net income to net cash provided by operating activities:
Gain on sale of product rights		$ (52.6)